Stay updated with breaking news from Experimental Therapeutics Next Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- MEKanistic Therapeutics, a pioneering biotechnology company revolutionizing kinase inhibitors for cancer treatment, announced today that its...
The OHSU Knight Cancer Institute’s Center for Experimental Therapeutics has been selected as the only cancer center in the Pacific Northwest to participate in a national consortium aimed at accelerating
PORTLAND, Ore. -- Oregon Health and Science University is joining a select group of medical research facilities to develop new cancer treatment therapies.
/PRNewswire/ -- Reaction Biology Corporation ("Reaction"), an industry-leading provider of drug discovery services, today announced that it has been selected...
James H. Doroshow, M.D. Director, Division of Cancer Treatment and Diagnosis As the National Cancer Institute (NCI) Deputy Director for Clinical and Translational Research, Dr. James H. Doroshow works closely with the NCI director and other deputy directors to carry out NCI’s mission, particularly as it relates to clinical trials and translational investigations. In early 2020, as part of NCI’s response to the COVID-19 pandemic, Dr. Doroshow led the rapid launch of the NCI COVID-19 in Cancer Patients Study (NCCAPS). In this natural history study, researchers will follow 2,000 individuals ...